Can a new drug outperform standard care for head and neck cancer?

NCT ID NCT07758621

First seen Aug 11, 2026 · Last updated Aug 12, 2026 · Updated 1 time

Summary

This trial is testing whether an experimental drug called SYS6010 can better control advanced head and neck cancer compared to standard single-drug treatments. It involves about 340 adults aged 18-75 whose cancer has returned or spread and who have already tried platinum-based chemotherapy and PD-(L)1 inhibitors. Participants will be randomly assigned to receive either SYS6010 or one of several standard chemotherapy or targeted therapy options. The study will measure how well the drug shrinks tumors and whether it helps people live longer.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
SYS6010, an experimental drug given by IV, compared with standard single-drug options (docetaxel, methotrexate, paclitaxel, or cetuximab).
What this could lead to
If SYS6010 works, it could offer a new, more effective treatment option for people with advanced head and neck cancer who have run out of standard options.
What could go wrong
This is an early-phase 3 trial, so results are not guaranteed. The drug may not be more effective than existing treatments, and it could have side effects that outweigh benefits.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEAD AND NECK SQUAMOUS CELL CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

head and neck squamous cell carcinoma Squamous Cell Carcinoma of Head and Neck

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

More trials for these conditions

Other studies related to the condition(s) this trial covers.